Swallow a sponge, skip the scope: new test could spot esophagus condition

NCT ID NCT06803927

Recruiting now Diagnosis Sponsor: Cyted Health Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests a simple, non-invasive device called EndoSign, which is a sponge on a string that you swallow in a capsule. The sponge collects cells from the esophagus, which are then tested for signs of Barrett's esophagus, a condition that can lead to cancer. The results will be compared to standard endoscopy and biopsies. The trial involves 700 participants who either have Barrett's esophagus or are at high risk for it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EndoSign Cell Collection Device (sponge on a string) with methylation biomarker test
What this could lead to: If successful, this could offer a simple, non-invasive way to screen for Barrett's esophagus, potentially catching it early and reducing the need for regular endoscopies.
What could go wrong: This is a diagnostic study, not a treatment. The test may not be as accurate as endoscopy, and results need further validation before widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Barrett esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARRETT ESOPHAGUS

Contacts and locations

Locations

Gastroenterology Practice
RECRUITING

Cordova, Tennessee, 38138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.